Incannex Healthcare Inc
IXHL
Company Profile
Business description
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Contact
8 Century Circuit Norwest
Suite 105
SydneyNSW3000
AUST: +61 409840786
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
9
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks
Chart of the Week: Largest share price falls during earnings
Opportunities arise when the market overreacts, and good quality companies are mispriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.20 | 10.40 | -0.11% |
| CAC 40 | 7,743.93 | 34.12 | 0.44% |
| DAX 40 | 24,046.21 | 106.66 | -0.44% |
| Dow JONES (US) | 45,565.23 | 147.16 | 0.32% |
| FTSE 100 | 9,255.50 | 10.30 | -0.11% |
| HKSE | 25,032.08 | 169.68 | -0.67% |
| NASDAQ | 21,590.14 | 45.87 | 0.21% |
| Nikkei 225 | 42,790.60 | 270.33 | 0.64% |
| NZX 50 Index | 12,920.19 | 58.35 | 0.45% |
| S&P 500 | 6,481.40 | 15.46 | 0.24% |
| S&P/ASX 200 | 8,969.10 | 1.40 | -0.02% |
| SSE Composite Index | 3,803.08 | 2.73 | 0.07% |